Drug-induced vasculitis

Vascular injury due to drugs is recognized as a distinct entity under the Chapel Hill Consensus Conference 2012 definitions for vasculitis. Drug-induced vasculitis (DIV) may affect various types of vessels. Isolated cutaneous leukocytoclastic vasculitis is most commonly seen in association with anti...

Full description

Bibliographic Details
Main Authors: Durga Prasanna Misra, Pallavi Patro, Aman Sharma
Format: Article
Language:English
Published: SAGE Publishing 2019-01-01
Series:Indian Journal of Rheumatology
Subjects:
Online Access:http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=3;epage=9;aulast=Misra
_version_ 1826910386643795968
author Durga Prasanna Misra
Pallavi Patro
Aman Sharma
author_facet Durga Prasanna Misra
Pallavi Patro
Aman Sharma
author_sort Durga Prasanna Misra
collection DOAJ
description Vascular injury due to drugs is recognized as a distinct entity under the Chapel Hill Consensus Conference 2012 definitions for vasculitis. Drug-induced vasculitis (DIV) may affect various types of vessels. Isolated cutaneous leukocytoclastic vasculitis is most commonly seen in association with antibiotics and nonsteroidal anti-inflammatory drugs. Drug-induced antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis has been classically associated with cocaine (alone or contaminated with levamisole), antithyroid drugs (propylthiouracil, methimazole, carbimazole) and hydralazine; minocycline often mimics medium-vessel vasculitis, with ANCA positivity. Drug-induced large-vessel vasculitis remains rare; however, it has been reported with anticancer agents targeting immune pathways, including immune checkpoint inhibitors. Cerebral vasculitis has been associated with oral or topical sympathomimetic drug use. Operational pathogenetic mechanisms in DIV include immune complex deposition, abnormal generation of neutrophil extracellular traps, and bypassing of normal immune checkpoints like that between programmed cell death ligand 1 on dendritic cells and programmed cell death 1 on T-lymphocytes. DIV can have an unpredictable course, and a significant proportion of patients require immunosuppressive therapy in addition to drug withdrawal.
first_indexed 2024-04-11T23:22:44Z
format Article
id doaj.art-f5f20396b2cd48759635fb3a08b0cca3
institution Directory Open Access Journal
issn 0973-3698
0973-3701
language English
last_indexed 2025-02-17T09:58:37Z
publishDate 2019-01-01
publisher SAGE Publishing
record_format Article
series Indian Journal of Rheumatology
spelling doaj.art-f5f20396b2cd48759635fb3a08b0cca32025-01-02T04:45:17ZengSAGE PublishingIndian Journal of Rheumatology0973-36980973-37012019-01-011453910.4103/0973-3698.272156Drug-induced vasculitisDurga Prasanna MisraPallavi PatroAman SharmaVascular injury due to drugs is recognized as a distinct entity under the Chapel Hill Consensus Conference 2012 definitions for vasculitis. Drug-induced vasculitis (DIV) may affect various types of vessels. Isolated cutaneous leukocytoclastic vasculitis is most commonly seen in association with antibiotics and nonsteroidal anti-inflammatory drugs. Drug-induced antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis has been classically associated with cocaine (alone or contaminated with levamisole), antithyroid drugs (propylthiouracil, methimazole, carbimazole) and hydralazine; minocycline often mimics medium-vessel vasculitis, with ANCA positivity. Drug-induced large-vessel vasculitis remains rare; however, it has been reported with anticancer agents targeting immune pathways, including immune checkpoint inhibitors. Cerebral vasculitis has been associated with oral or topical sympathomimetic drug use. Operational pathogenetic mechanisms in DIV include immune complex deposition, abnormal generation of neutrophil extracellular traps, and bypassing of normal immune checkpoints like that between programmed cell death ligand 1 on dendritic cells and programmed cell death 1 on T-lymphocytes. DIV can have an unpredictable course, and a significant proportion of patients require immunosuppressive therapy in addition to drug withdrawal.http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=3;epage=9;aulast=Misrahydralazineimmune checkpoint inhibitorleukocytoclastic vasculitislevamisoleminocyclinepropylthiouracil
spellingShingle Durga Prasanna Misra
Pallavi Patro
Aman Sharma
Drug-induced vasculitis
Indian Journal of Rheumatology
hydralazine
immune checkpoint inhibitor
leukocytoclastic vasculitis
levamisole
minocycline
propylthiouracil
title Drug-induced vasculitis
title_full Drug-induced vasculitis
title_fullStr Drug-induced vasculitis
title_full_unstemmed Drug-induced vasculitis
title_short Drug-induced vasculitis
title_sort drug induced vasculitis
topic hydralazine
immune checkpoint inhibitor
leukocytoclastic vasculitis
levamisole
minocycline
propylthiouracil
url http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=5;spage=3;epage=9;aulast=Misra
work_keys_str_mv AT durgaprasannamisra druginducedvasculitis
AT pallavipatro druginducedvasculitis
AT amansharma druginducedvasculitis